Literature DB >> 31926914

Copro-molecular study of Entamoeba infection among the indigenous community in Malaysia: A first report on the species-specific prevalence of Entamoeba in dogs.

Romano Ngui1, Nur-Amirah Hassan2, Nor Muhammad Soffyan Nordin2, Norashikin Mohd-Shaharuddin2, Li Yen Chang3, Cindy Shuan Ju Teh3, Kek Heng Chua4, Boon Pin Kee4, See Ziau Hoe5, Yvonne Ai Lian Lim2.   

Abstract

BACKGROUND: Entamoeba is a free-living protozoan parasitic species that infect a variety of hosts. In humans, Entamoeba histolytica is the causative agent of amoebiasis. Entamoeba species has also been reported in dogs. However, little is known about the molecular epidemiology and the specific species of this parasite in dogs globally, including Malaysia. As dogs are important companion animals for the indigenous community, and close contact with dogs is part of the natural living conditions for this community, this study aims to determine the prevalence and molecular epidemiology of Entamoeba species in human and dogs in Malaysia.
METHOD: The presence of Entamoeba species was examined in 504 fresh fecal samples, collected randomly from 411 humans and 93 dogs using microscopy and polymerase chain reaction (PCR) amplifying 16 s ribosomal RNA (rRNA). Data was analyzed using appropriate statistical analysis.
RESULTS: The microscopy data showed an overall occurrence of Entamoeba species of 26.3% (108/411) and 36.6% (34/93) in humans and dogs respectively. In humans, the most common species was a single infection of E. dispar (26.5%; 13/49), followed by E. histolytica and E. moshkovskii, (20.4% for each species respectively). Double infection of E. dispar + E. moshkovskii was detected at 10.2%, followed by E. dispar + E. histolytica (8.2%) and E. moshkovskii and E. histolytica (6.1%). 8.2% of the samples had triple infection with all three species. In animals, E. moshkovskii (46.7%) was the most common species detected, followed by E. histolytica, and E. dispar, at 20.0% and 13.3% respectively. Double infection with E. moshkovskii + E. histolytica and a triple infection were found in 2 samples (13.3%) and 1 (6.7%) sample respectively. Risk factor analysis showed that members of the community who used untreated water were more prone to be infected with Entamoeba.
CONCLUSION: This study provides information on the species-specific occurrence of Entamoeba infection, the potential risk factors and their zoonotic potential to humans. This is the first report to describe the molecular occurrence of Entamoeba species in dogs in Malaysia. The presence of pathogenic Entamoeba species implies that dogs could be a reservoir or mechanical host for human amoebiasis. Further studies need to be conducted to better understand the transmission dynamics and public health significance of Entamoeba species in human and animal hosts.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amoebiasis; E. dispar; E. histolytica; E. moshkovskii; Malaysia; Risk factors; Zoonotic

Year:  2020        PMID: 31926914     DOI: 10.1016/j.actatropica.2020.105334

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

1.  First Molecular Identification of Ancylostoma Species in Dogs in a Rural Tea Estate Community in Sri Lanka and the Detection of Other Zoonotic Gastro-intestinal Parasites.

Authors:  Tilini K De Silva; Rupika S Rajakaruna; Keerthi M Mohotti; R P V J Rajapakse; Piyumali K Perera
Journal:  Acta Parasitol       Date:  2022-04-06       Impact factor: 1.534

2.  Prevalence of intestinal protozoan parasites among school children in africa: A systematic review and meta-analysis.

Authors:  Khalid Hajissa; Md Asiful Islam; Abdoulie M Sanyang; Zeehaida Mohamed
Journal:  PLoS Negl Trop Dis       Date:  2022-02-11

3.  Molecular identification of Entamoeba histolytica, E. dispar, and E. moshkovskii in children with diarrhea from Maracaibo, Venezuela

Authors:  Zulbey Rivero; Lisbeth Villareal; Ángela Bracho; Carem Prieto; Rafael Villalobos
Journal:  Biomedica       Date:  2021-05-31       Impact factor: 0.935

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.